US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 agonist
biotech · Non-muscle Invasive Bladder Cancer · Intestinal Failure · TARA
Protara Therapeutics
Protara Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
2017 Founded
56 Employees
Public company Type
TARA · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2017
- Employees
- 56
- Programs
- 7
- Drugs
- 10
- Patents
- 2
Protara Therapeutics pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Protara Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Protara Therapeutics in public FDA and regional records.
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Protara Therapeutics's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Protara Therapeutics in public FDA and regional records.
-
Development asset linked to Protara Therapeutics in public FDA and regional records. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to Protara Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to Protara Therapeutics in public FDA and regional records.